Human papillomavirus: a predictor of better survival in ocular surface squamous neoplasia patients

Sheetal Chauhan,1 Seema Sen,1 Anjana Sharma,2 Lalit Dar,3 Seema Kashyap,1 Pankaj Kumar,3 Mandeep Singh Bajaj,4 Radhika Tandon5

ABSTRACT

Background Although human papillomavirus (HPV) has been implicated in the pathogenesis of ocular surface squamous neoplasia (OSSN), no study has so far dealt with the prognostic role of HPV. In this study the presence and significance of HPV in OSSN and its correlation with p16INK4a immunoexpression was determined.

Methods HPV was detected by HPV-L1 capsid gene-specific multiplex PCR using PGMY09/11 primers, and genotyping was done by linear array on 64 OSSN patients and 15 conjunctival controls. p16INK4a immunoexpression as a marker for HPV presence was also evaluated.

Results The HPV genome was detected in 11% of cases by multiplex PCR, and all positives belonged to a high-risk HPV16 genotype. p16INK4a Overexpression was seen in 28% (18/64) of cases. Control conjunctival tissues were negative for HPV and p16INK4a expression. The presence of HPV was associated with significantly improved disease-free survival (p = 0.02) as well as p16INK4a overexpression (p = 0.001). The sensitivity and specificity of p16INK4a as a marker for HPV presence was 86% and 79%, respectively, with a positive predictive value of 33% and a negative predictive value of 98%.

Conclusions The results of this study point towards HPV as a predictor of better survival in a subset of HPV-positive OSSN patients. Although p16INK4a immunoexpression is a useful indicator of HPV presence in OSSN, confirmation by multiplex PCR is necessary.

INTRODUCTION

Ocular surface squamous neoplasia (OSSN) encompasses a spectrum of conjunctival, limbal and corneal neoplasias, which include conjunctival intraepithelial neoplasias (CIN) or dysplasia at the one end to invasive squamous cell carcinoma (SCC) at the other. It is the most common ocular surface tumour and the third most common oculo-orbital tumour after melanoma and lymphoma, with a worldwide incidence ranging between 0.02 and 3.5 per 100,000. Although most of the tumours are localised and slowly growing, they have the capability of causing severe ocular morbidity and mortality if neglected.1,2

The pathogenesis of these tumours has been attributed classically to abnormal maturation of the epithelium induced by ultraviolet irradiation in combination with other factors including human papillomavirus (HPV), HIV infection or organ transplant recipients (due to immunosuppression), and in genetically predisposed states, such as xeroderma pigmentosum.3

HPV have been associated with a variety of benign and malignant epithelial lesions. High-risk HPV types 16 and 18 have been implicated as aetiological agents for the development of cervical SCC.4 Studies on OSSN from different geographical regions have reported wide variation in HPV positivity between 0% and 100%.5–10 A few published studies from India have shown no association of HPV with OSSN.11–12

In HPV-associated tumours, the expression of tumour suppressor protein p16INK4a is increased due to inactivation of retinoblastoma protein by high-risk HPV oncoprotein E7, unlike other cancers in which p16INK4a gets inactivated.13 14 Overexpression of p16INK4a is therefore considered a reliable marker for HPV-induced cervical intraepithelial neoplasia and head and neck SCC.15

The present study was planned to determine the presence and genotype of HPV DNA in OSSN and its association with survival. The utility of p16INK4a immunoexpression for predicting HPV in OSSN was also evaluated.

MATERIALS AND METHODS

Patient and control group selection

Sixty-four patients with OSSN (44 SCC, 20 CIN) and 15 controls (conjunctival epithelium-ectomy tissues from limbal stem cell deficiency patients) from the years 2008–10 were enrolled in this study and approval was obtained from the institute ethics committee. After obtaining written consent fresh tissues from cases and controls were stored at −70°C for molecular studies, and the remaining tissue was fixed in 10% neutral buffered formalin and embedded in paraffin wax for histopathological examination and immunohistochemical analysis.

Clinical features including hours of exposure to solar ultraviolet irradiation and the presence of predisposing conditions such as xeroderma pigmentosum were recorded. Radiological details were also recorded.

Haematoxylin-eosin stained sections were examined to confirm the diagnosis of OSSN and the cases were classified as CIN or SCC. The CIN cases were further classified as mild, moderate or severe dysplasia based on the extent of epithelial involvement, and SCC cases were classified as well or poorly differentiated depending on the extent of keratinisation.16

Detection of HPV by multiplex PCR

DNA extraction from all 64 fresh tissue specimens was performed using the QIAGen DNA mini kit (Qiagen, Hilden, Germany) following the
manufacturer’s instructions. The extracted DNA was quantified using a Nanodrop spectrophotometer (Nanodrop Technologies, Wilmington, Delaware, USA). The quality of extracted DNA was determined by β-globin-specific PCR using GH20/GH21 primer. Briefly, a 40 ng/μl aliquot of genomic DNA was added as a template to a PCR master mixture containing 1× PCR buffer (100 Mm Tris-HCl, 500 Mm KCl, pH 8.3), 200 μM each deoxynucleoside triphosphate, 200 nM primer, 1.5 mM MgCl₂ and 2.5 U of Ampli Taq Gold DNA polymerase. PCR was performed using the following conditions: 10 min at 95°C, followed by 30 s at 95°C, 1 min at 53°C, 1 min at 72°C and 10 min at 72°C for 35 cycles. DNA extracted from all 64 samples and 15 controls was amplified using β-globin, which showed a product of 450 bp, confirming the quality of DNA to be suitable for PCR.

The HPV-L1 capsid gene-specific consensus primer, PGMY09/11, which is an improvement for quality assurance was used for HPV detection. This primer detects all the major HPV types. The PCR assay was performed using a 40 ng/μl aliquot of DNA in master mixture containing 1× PCR buffer, 200 μM each deoxynucleoside triphosphate, 200 nM primer, 4.0 mM MgCl₂ and 7.5 U of Ampli Taq Gold DNA polymerase. Forty cycles of amplification were performed using the following conditions: 9 min at 94°C, followed by 1 min at 94°C, 1 min at 55°C and 1 min at 72°C.

For each reaction, DNA extracted from CaSki (HPV16) and HeLa (HPV18) cell lines served as positive and C33A (HPV negative) cell line and deionised water instead of the DNA template served as a negative control for HPV-specific PCR assay.

HPV genotyping by linear array
Genotyping of positive samples was done using the HPV linear array kit (Roche Molecular System, Branchburg, New Jersey, USA) following the manufacturer’s instructions. Briefly, DNA was isolated and for each reaction, 20 μl of extracted DNA was subjected to PCR amplification using the HPV consensus PCR (Roche Molecular Systems Inc., Alameda, California, USA). This method utilises biotinylated primers (PGMY09/PGMY11) that amplify a 450 bp fragment of the L1 open reading frame of 37 HPV genotypes. A control set of biotinylated primers simultaneously amplifies a 268 bp fragment of the human β-globin gene in each reaction. PCR products were then denatured and hybridised to separate HPV genotyping strips containing an immobilised array of 37 different HPV probes. Hybridised PCR products were visualised using a streptavidin-horseradish peroxidase detection system. Negative and positive controls (provided in the kit) were run with each batch of specimens tested.

P16INK4a immunohistochemistry
Immunohistochemistry for p16INK4a was performed on 64 cases and 15 control conjunctival tissues. Unstained sections of 4–5 μm thickness were cut on polylisine-coated slides from the formalin-fixed paraffin-embedded tissues and subjected to immunohistochemical analysis using the avidin-biotin indirect method. Briefly, sections were deparaffinised in xylene, dehydrated and subjected to heat antigen retrieval in citrate buffer (pH 6.0) for 20 min. Endogenous peroxidase activity was blocked by 3% H₂O₂. The slides were incubated with primary mouse IgG2b against p16INK4a (clone 6H12; prokaryotic recombinant fusion protein corresponding to the entire human p16INK4a molecule) obtained from Novocastra Laboratories Ltd. (UK) at a dilution of 1:50 in a humidified chamber at 4°C overnight, followed by incubations with biotinylated-linked secondary antibody and peroxidase labelled streptavidin (Dako Cytomation LSAB+System-HRP kit). The sections were visualised using 3, 3-diaminobenzidine peroxidase substrate for 3–4 min, then counterstained with haematoxylin and examined by light microscopy. p16INK4a-positive cervical SCC served as a positive control. Primary antibody was replaced by Tris-buffered saline in the negative control. Immunoreactivity was considered positive when more than 10% of the cells showed nuclear as well as cytoplasmic positivity.¹⁷ ¹⁸

Statistical analysis
Statistical analysis was performed with Windows SPSS V11.0. The relationship between HPV, p16INK4a status and clinicopathological variables such as age, sex, laterality, surgical intervention, histopathological differentiation, and tumour size, orbital and intraocular invasion was evaluated using a contingency table, and further analysed using Fisher’s exact test.

p16INK4a Immunostaining was evaluated in terms of sensitivity, specificity and predictive value of the test for detecting HPV. The κ statistics was used to assess the degree of agreement between p16INK4a and HPV tests. κ Values between 0.40 and 0.75 are regarded as fair to good agreement beyond chance, values less than 0.40 as poor agreement beyond chance, and values greater than 0.75 as excellent agreement beyond chance. Disease-free survival curves were constructed using the Kaplan–Meier method and compared using the log-rank test.

RESULTS
Clinical and histopathology features
The mean age of the 64 OSSN patients was 64±16 years (6–84 years) with a marked male preponderance (male : female 3.6 : 1). Limbus was involved in 55 of 64 cases (54.6%). The duration of disease varied between 4 months and 10 years (mean 2.3±2.3 years). A history of sunlight exposure greater than 5 h was observed in 41 of 64 (64%) patients. The majority of the patients (64.3%) came from a poor socioeconomic background (below the poverty line). A history of associated ocular pathology was present in 10 patients (pterygium, ptosis naevus, cyst excision, cataract surgery), and six gave a history of ocular trauma to the affected eye. Three patients had xero-derma pigmentosum and none was an organ transplant recipient. Radiologically, orbital invasion was present in 18 of 64 (28%). Wide surgical excision was performed in 46 (72%) and the rest underwent exenteration for extensive disease. Gross examination revealed a tumour diameter of 0.4–6.0 cm (mean 2.4±1.9 cm), and on light microscopy 69% (44/64) were SCC cases (22 well and 22 poorly differentiated) and 20 of 64 (31%) were CIN cases (seven mild, six moderate and seven severe dysplasia). Intraocular invasion was seen in six of 64 (10%) cases (tables 1–4).

Clinical outcome
Follow-up data were available in 48 (75%) OSSN cases over a period of 16–36 months (median 22 months). Recurrence developed in eight (17%) patients, lymph node metastasis in four (8.3%) and tumour-related deaths in four (8.3%). All four patients with SCC who died had a tumour size greater than 3 cm with orbital involvement.

Multiplex PCR and HPV genotyping results
HPV DNA was detected in seven out of 64 cases (11%) using PGMY09/11 consensus primer mediated PCR assay. Of the seven HPV-positive cases, four were SCC patients (two well and two poorly differentiated) and three had CIN (one
moderate and two severe dysplasia). All the 15 conjunctival controls were negative for HPV.

Of the 37 HPV genotypes screened by linear array, only HPV16 was detected in the seven HPV-positive OSSN cases that were analysed (figures 1 and 2).

Table 1  Association of HPV with location of OSSN

<table>
<thead>
<tr>
<th>Location</th>
<th>HPV positive (n=7)</th>
<th>HPV negative (n=57)</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bulbar conjunctiva</td>
<td>4</td>
<td>10</td>
<td>0.06 (NS)</td>
</tr>
<tr>
<td>Limbus (35)</td>
<td>2</td>
<td>33</td>
<td></td>
</tr>
<tr>
<td>Orbital or intraocular</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Tumour size, cm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1 (n=27)</td>
<td>1</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>&gt;1 (n=37)</td>
<td>6</td>
<td>31</td>
<td>0.2 (NS)</td>
</tr>
</tbody>
</table>

*Fisher’s exact test. HPV, human papillomavirus; NS, not significant; OSSN, ocular surface squamous neoplasia.

Table 2  Correlation of HPV with clinical features in OSSN

<table>
<thead>
<tr>
<th>Clinical characteristics</th>
<th>Total (n=64)</th>
<th>HPV positive (n=7)</th>
<th>HPV negative (n=57)</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;50</td>
<td>18 (28%)</td>
<td>4</td>
<td>8</td>
<td>0.6 (NS)</td>
</tr>
<tr>
<td>&gt;50</td>
<td>46 (72%)</td>
<td>3</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>50 (78%)</td>
<td>4</td>
<td>46 (92%)</td>
<td>0.8 (NS)</td>
</tr>
<tr>
<td>Female</td>
<td>14 (22%)</td>
<td>3</td>
<td>11 (79%)</td>
<td></td>
</tr>
<tr>
<td>Laterality</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left</td>
<td>41 (64%)</td>
<td>37 (90%)</td>
<td>4 (10%)</td>
<td>0.7 (NS)</td>
</tr>
<tr>
<td>Right</td>
<td>23 (36%)</td>
<td>3 (13%)</td>
<td>20 (87%)</td>
<td></td>
</tr>
<tr>
<td>Sunlight exposure, hours</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;5</td>
<td>41 (64%)</td>
<td>5 (12%)</td>
<td>36 (88%)</td>
<td>0.9 (NS)</td>
</tr>
<tr>
<td>&lt;5</td>
<td>23 (36%)</td>
<td>2 (9%)</td>
<td>7 (91%)</td>
<td></td>
</tr>
<tr>
<td>Socioeconomic status</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poor</td>
<td>54 (84%)</td>
<td>7 (13%)</td>
<td>47 (87%)</td>
<td>0.6 (NS)</td>
</tr>
<tr>
<td>Others</td>
<td>10 (16%)</td>
<td>0 (0%)</td>
<td>10 (100%)</td>
<td></td>
</tr>
<tr>
<td>History of past injury</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>6 (9%)</td>
<td>0 (0%)</td>
<td>6 (100%)</td>
<td>0.9 (NS)</td>
</tr>
<tr>
<td>No</td>
<td>58 (91%)</td>
<td>7 (12%)</td>
<td>51 (88%)</td>
<td></td>
</tr>
<tr>
<td>Associated ocular pathology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>13 (20%)</td>
<td>0 (0%)</td>
<td>13 (100%)</td>
<td>0.3 (NS)</td>
</tr>
<tr>
<td>No</td>
<td>41 (68%)</td>
<td>7 (17%)</td>
<td>34 (36%)</td>
<td></td>
</tr>
<tr>
<td>Surgical intervention</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biopsy</td>
<td>46 (72%)</td>
<td>3 (7%)</td>
<td>43 (97%)</td>
<td>0.09 (NS)</td>
</tr>
<tr>
<td>Exenteration</td>
<td>18 (28%)</td>
<td>4 (22%)</td>
<td>14 (78%)</td>
<td></td>
</tr>
<tr>
<td>Metastasis†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td>4 (6%)</td>
<td>0 (0%)</td>
<td>4 (100%)</td>
<td>0.9 (NS)</td>
</tr>
<tr>
<td>Absent</td>
<td>60 (94%)</td>
<td>4 (7.0%)</td>
<td>56 (93%)</td>
<td></td>
</tr>
</tbody>
</table>

*Fisher’s exact test. HPV, human papillomavirus; NS, not significant; OSSN, ocular surface squamous neoplasia.

Association of HPV positivity with clinicopathological parameters

Survival curves of 48 OSSN patients by Kaplan–Meir analysis showed a significantly improved disease-free survival in HPV-positive OSSN cases (p=0.02) (figure 3).

Both bulbar as well as limbal conjunctival locations of OSSN significantly correlated with HPV presence (p=0.0002). However, no statistically significant association was observed between HPV presence and any other clinicopathological feature (tables 1–3).

Correlation of p16INK4a immunoexpression with HPV in OSSN

Six of the seven HPV-positive cases showed p16INK4a expression (figure 4). However, of the 28% (18/64) of OSSN cases positive for p16INK4a only 53% (6/11) were HPV positive. This correlation between p16INK4a expression and HPV positivity was found to be statistically significant (p=0.001). p16INK4a Overexpression demonstrated 86% sensitivity and 79% specificity in detecting HPV, with a positive predictive value of 33% and a negative predictive value of 98%. The agreement between the two tests for HPV detection (p16INK4a and linear array) was found to be fair (k=0.4). All 15 control conjunctival tissues were negative for HPV (table 4).

DISCUSSION

In the multifactorial aetiology and pathogenesis of OSSN the contribution of HPV remains unresolved. Despite several studies over the past three decades on HPV detection in OSSN by PCR, very few have used fresh tumour tissue. Most published series have used MY09/11 design (nested, broad spectrum or type specific) and the size of the amplified product. Most published series have used MY09/11
or GP5/6 consensus primers in OSSN.9,10 Earlier studies from India on formalin-fixed paraffin-embedded samples did not show any association between OSSN and HPV by PCR or immunohistochemistry.11,12

In the present study, therefore, we used more specific and sensitive multiplex PCR (PGMY09/11 primer) on fresh tumour tissues from OSSN cases. This improved PGMY09/11 primer has a greater potential to detect both the newer HPV types as well as the classic genital HPV types.20 HPV has been detected on formalin-fixed paraffin-embedded tissues by linear array in head and neck cancer and retinoblastoma cases. In retinoblastoma the detection rate was 14% in archival tissues as compared to 58% in fresh cases.21,22

As most studies on HPV genotyping in OSSN are limited to detect only a few high-risk types, we encompassed a wide spectrum of as many as 37 genotypes by linear array, including the major high-risk types. HPV16 was detected in 11% of our OSSN cases with a positivity of 9% in SCC patients and 15% in dysplastic cases. Although earlier studies have also demonstrated HPV16 in OSSN,6,23 others have demonstrated HPV18 as well as multiple genotypes in their cases.8,9 However, multiple high-risk-HPV types are reported more commonly in cervical neoplasia.24

Although the incidence of orbital and intraocular invasion was higher in this study (38%) compared to 2–13% reported by others,25 survival analysis revealed HPV16-positive OSSN cases to have a better overall survival. Improved survival in HPV-positive cases has earlier been reported in cervical, head and neck, as well as oral carcinoma;26–28 however, to the best of our knowledge this is the first study to report the impact of HPV on the survival of OSSN patients.

Overexpression of p16INK4a in OSSN in our study was significantly associated with HPV positivity unlike histologically normal conjunctival tissues, which were negative both for HPV as well as p16INK4a. Although Auw-Haedrich et al.29 have reported HPV and p16INK4a positivity in CIN; they did not observe any association between p16INK4a and HPV. In another study by Kuo et al.30 the absence of p16INK4a expression was observed in both HPV-positive CIN cases as well as HPV-negative normal conjunctiva. Both those studies had limitations of small sample size and SCC cases were not included in the study. Recent studies in cervical, head–neck, oral SCC and intraepithelial neoplasia have revealed p16INK4a to be a biomarker for high-risk-HPV detection.31,32

Figure 1: PCR amplification of HPV L-1 consensus showing the amplimer of 450 bp. Lane 1: Negative control (dH2O), Lane 2: HPV positive cell line (Hela DNA), Lane 3-7: OSSN samples. Lane 3, 5 and 7 shows HPV positive cases, Lane 8: HPV negative cell line (C33a DNA), Lane 9: Control conjunctival tissue, Lane M: 100 bp DNA molecular weight marker.

Figure 2: Identification of human papillomavirus (HPV) genotypes in ocular surface squamous neoplasia using linear array. HPV16 was detected in cases 2 and 6.

Figure 3: Kaplan–Meier survival curves for disease-free survival stratified according to the human papillomavirus (HPV) infection in patients with ocular surface squamous neoplasia. The disease-free survival rate of the HPV-positive group was significantly better (p=0.02).

Figure 4: p16INK4a immunostaining to show strong nuclear and cytoplasmic positivity in a case of squamous cell carcinoma (a and b) (magnifications ×200 and ×400).
In conclusion, HPV16 DNA was detected in a subset of OSSN cases with improved disease-free survival. The clinical relevance of this observation needs to be validated in a larger HPV-positive OSSN patient cohort. Although p16\textsuperscript{INK4a} immunorelevance of this observation needs to be validated in a larger OSSN cases with improved disease-free survival. The clinical assistance in standardising experiments and data analysis. MSB and RT contributed analysis and interpretation of data as well as drafting the article. PK provided in carrying out diagnostic tests, results analysis and revising article. SK contributed to intellectual content and approved final version to be submitted. LD provided support financially supported by an intramural grant from the All India Institute of Medical Sciences, New Delhi. SD is grateful to the Indian Council of Medical Research, New Delhi, for providing a senior research fellowship.

Competing interests None.

Patient consent Obtained.

Ethics approval Ethics approval was obtained from the institute ethics committee, AIIMS (New Delhi).

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

Human papillomavirus: a predictor of better survival in ocular surface squamous neoplasia patients

Sheetal Chauhan, Seema Sen, Anjana Sharma, Lalit Dar, Seema Kashyap, Pankaj Kumar, Mandeep Singh Bajaj and Radhika Tandon

*Br J Ophthalmol* 2012 96: 1517-1521 originally published online August 31, 2012
doi: 10.1136/bjophthalmol-2012-301907

Updated information and services can be found at:
http://bjo.bmj.com/content/96/12/1517

These include:

**References**

This article cites 31 articles, 6 of which you can access for free at:
http://bjo.bmj.com/content/96/12/1517#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

Editor’s choice (112)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/